Literature DB >> 21788452

Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains.

Zania Stamataki, Stephen Coates, Sergio Abrignani, Michael Houghton, Jane A McKeating.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21788452      PMCID： PMC3203385          DOI： 10.1093/infdis/jir399

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  6 in total

1.  Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain.

Authors:  Thomas Vanwolleghem; Jens Bukh; Philip Meuleman; Isabelle Desombere; Jean-Christophe Meunier; Harvey Alter; Robert H Purcell; Geert Leroux-Roels
Journal:  Hepatology       Date:  2008-06       Impact factor: 17.425

2.  Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.

Authors:  Ranjit Ray; Keith Meyer; Arup Banerjee; Arnab Basu; Stephen Coates; Sergio Abrignani; Michael Houghton; Sharon E Frey; Robert B Belshe
Journal:  J Infect Dis       Date:  2010-09-15       Impact factor: 5.226

3.  Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.

Authors:  Mansun Law; Toshiaki Maruyama; Jamie Lewis; Erick Giang; Alexander W Tarr; Zania Stamataki; Pablo Gastaminza; Francis V Chisari; Ian M Jones; Robert I Fox; Jonathan K Ball; Jane A McKeating; Norman M Kneteman; Dennis R Burton
Journal:  Nat Med       Date:  2007-12-06       Impact factor: 53.440

4.  Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies.

Authors:  Zania Stamataki; Stephen Coates; Matthew J Evans; Mark Wininger; Kevin Crawford; Christine Dong; Yiu-Lian Fong; David Chien; Sergio Abrignani; Peter Balfe; Charles M Rice; Jane A McKeating; Michael Houghton
Journal:  Vaccine       Date:  2007-09-14       Impact factor: 3.641

5.  Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies.

Authors:  Jennifer M Timpe; Zania Stamataki; Adam Jennings; Ke Hu; Michelle J Farquhar; Helen J Harris; Anne Schwarz; Isabelle Desombere; Geert Leroux Roels; Peter Balfe; Jane A McKeating
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

Review 6.  Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

Authors:  Leonidas Stamatatos; Lynn Morris; Dennis R Burton; John R Mascola
Journal:  Nat Med       Date:  2009-08       Impact factor: 53.440
  6 in total
  30 in total

1.  Will there be a vaccine to protect against the hepatitis C virus?

Authors:  Benoît Callendret; Christopher M Walker
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

2.  Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.

Authors:  Michael Logan; John Law; Jason Alexander Ji-Xhin Wong; Darren Hockman; Amir Landi; Chao Chen; Kevin Crawford; Juthika Kundu; Lesley Baldwin; Janelle Johnson; Anita Dahiya; Gerald LaChance; Joseph Marcotrigiano; Mansun Law; Steven Foung; Lorne Tyrrell; Michael Houghton
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

Review 3.  Current progress in development of hepatitis C virus vaccines.

Authors:  T Jake Liang
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

4.  Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster.

Authors:  Jorge Reyes-del Valle; Cynthia de la Fuente; Mallory A Turner; Christoph Springfeld; Swapna Apte-Sengupta; Marie E Frenzke; Amelie Forest; Jillian Whidby; Joseph Marcotrigiano; Charles M Rice; Roberto Cattaneo
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

5.  Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77.

Authors:  Yi-Ping Li; Santseharay Ramirez; Lotte Mikkelsen; Jens Bukh
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

Review 6.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

7.  Structure-function analysis of hepatitis C virus envelope glycoproteins E1 and E2.

Authors:  Aparajita Nayak; Nagarajan Pattabiraman; Numrah Fadra; Radoslav Goldman; Sergei L Kosakovsky Pond; Raja Mazumder
Journal:  J Biomol Struct Dyn       Date:  2014-10-15

Review 8.  Status of hepatitis C virus vaccination: Recent update.

Authors:  Kouka Saadeldin Abdelwahab; Zeinab Nabil Ahmed Said
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

9.  Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.

Authors:  Alicja M Chmielewska; Mariarosaria Naddeo; Stefania Capone; Virginia Ammendola; Ke Hu; Luke Meredith; Lieven Verhoye; Malgorzata Rychlowska; Rino Rappuoli; Jeffrey B Ulmer; Stefano Colloca; Alfredo Nicosia; Riccardo Cortese; Geert Leroux-Roels; Peter Balfe; Krystyna Bienkowska-Szewczyk; Philip Meuleman; Jane A McKeating; Antonella Folgori
Journal:  J Virol       Date:  2014-03-05       Impact factor: 5.103

Review 10.  Immunopotentiating and Delivery Systems for HCV Vaccines.

Authors:  Alexander K Andrianov; Thomas R Fuerst
Journal:  Viruses       Date:  2021-05-25       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.